



BCRC Retreat 2021

This year's organization committee suggests, also based on your feedback that interested labs present one highlight project completed during the pandemic. Suggested talk structure: 10' project - 5' next steps - 5' discussion (20'). **3G rules apply for onsite participation. The talks will be streamed live.**

Best, D. Stroka, T. Marti and M.P. Tschan

BCRC Program (13:15h-17h)

Thursday, November 18

- | | |
|-------------|--|
| 13h15–13h30 | Short Welcome Note and presentation of the new PhD specialization Tumor Biology - Mario Tschan |
| 13h30–13h50 | <i>Matus Medo (Zimmer/Medova) – “Genomic characterization of head and neck squamous cell carcinoma metastases”</i> |
| 13h50–14h10 | <i>Jacopo Gavini (Stroka) “The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocellular carcinoma”</i> |
| 14h10–14h30 | <i>Chiara Pozzato (Konstantinidou) – “Combined inhibition of ERK5 and CDK5 synergistically suppress cell proliferation and induce cell death in non-small cell lung cancer.”</i> |
| 14h30–14h50 | <i>Darien Toledo Santamaria (von Gunten) “Impact of Siglec-7 ligands expression levels in survival of melanoma patients”</i> |
| 14h50–15h30 | Coffee Break |
| 15h30–15h50 | <i>Zhang Yang (Peng) “Combined FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer” (Zoom live streaming).</i> |
| 15h50–16h10 | <i>Federico La Manna (Kruithof-de Julio) “Patient-derived xenografts and organoids model therapy response in prostate cancer”</i> |
| 16h10–16h30 | <i>Carmen Widmer (Rottenberg) “Loss of NAA60 affects Pt drug efficacy in BRCA1/2-deficient mouse mammary tumors”</i> |
| 16h30–16h50 | <i>Simon April (Perren/Marinoni) “Patient-derived Islet-like Tumoroids phenocopy original Pancreatic Neuroendocrine Neoplasms and facilitate in vitro drug screening”</i> |
| 16h50–17h00 | Feedback/Suggestions for improvement BCRC events |
| 17h00– | Grab a drink and some chips |
-